T cell receptor gamma joining PGenealiases: JP · TCRGJP
Q-omics provides the consensus-scored TRGJP profile across patient tissues and cancer cell-line models. TRGJP expression is associated with patient survival in 9 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, TRGJP is differentially expressed in 1, with the highest sampling consensus in PRAD. Additionally, TRGJP RNA expression shows 6,996 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight STAD, PRAD, and LSCC as cancer lineages where TRGJP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRGJP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRGJP survival associations across molecular data types. TRGJP RNA expression shows survival associations in the most cancer types (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRGJP RNA expression–survival associations across cancer types. High TRGJP expression shows unfavorable associations in STAD, MESO, CESC, BRCA, THCA and KICH. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify STAD as the clearest survival context for TRGJP RNA expression.
This table summarizes TRGJP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in PRAD for RNA.
This table ranks reproducible tumor–normal expression differences for TRGJP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRGJP shows higher tumor expression in PRAD. The PRAD box plot shows higher TRGJP RNA expression in tumor versus normal tissue (log2 FC = +0.425, t-test p < 0.001).
This table shows molecular features associated with TRGJP in patient tissues and cancer cell lines. In patient samples, TRGJP shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
